VP
Syner-G Biopharma Group
Framingham, Massachusetts
Stacy M. Plum, Ph.D., joined Syner-G in early 2021 with
20 years of experience as a biotechnology industry
leader in the development of pharmaceutical products
with a focus on protein and cell-based therapeutics,
as well as vaccine development. An entrepreneur at
heart, Stacy thrives in driving unique programs into the
clinic and beyond to ultimately benefit the patient.
Stacy employs a risk-based strategic approach
guiding successful pharmaceutical development of
biologic programs. She has extensive expertise in
leading efforts from early-stage development through
approval with top pharmaceutical and biotechnology
companies. She provides scientific knowledge
combined with extensive command of technical CMC
components, regulatory, and QA requirements.
Stacy’s areas of expertise include the development of
plasma protein therapeutics, monoclonal antibodies,
fusion proteins, bispecifics, antibody drug conjugates,
gene therapies, cell-based therapeutics, and vaccines
from discovery to various stages of development,
including approval. She uses a phase appropriate
approach to foster accelerated development of
programs and ensures the CMC components are
sufficient to support regulatory submissions.
Stacy’s previous work experience includes Entremed,
Exocyte Therapeutics, Extreme Science, E6, and
Prometic Biotherapeutics (currently Liminal Biosciences).
She has a Bachelor of Science in Biology from Virginia
Tech and a Doctorate of Philosophy from Georgetown
University. She has generated over 10 successful IND,
IMPD, and BLA submissions; and authored 15 scientific
publications, 8 patents, and over 20 abstracts.
Disclosure information not submitted.
Tuesday, May 14, 2024
3:15 PM – 3:30 PM PT